InvestorsHub Logo
Followers 144
Posts 10941
Boards Moderated 0
Alias Born 04/02/2006

Re: None

Thursday, 10/19/2017 11:31:08 AM

Thursday, October 19, 2017 11:31:08 AM

Post# of 2537
Dynavax launches study to identify the best dose of inhaled DV281 for combo study with PD-1 inhibitor in lung cancer

Oct. 19, 2017 11:26 AM ET|About: Dynavax Technologies C... (DVAX)|By: Douglas W. House, SA News Editor

•Dynavax (DVAX +1.7%) initiates a 24-subject, open-label Phase 1b dose escalation study to identify the optimum dose of inhaled toll-like receptor 9 (TLR9) agonist DV281 in patients with non-small cell lung cancer (NSCLC). The most effective dose will be used in an expansion phase where it will be evaluated with a PD-1 inhibitor (e.g., Merck's Keytruda).

•The company says it specifically formulated DV281 for inhalation to facilitate the delivery of a TLR9 agonist to lung tumors, not easily accessible via intratumoral injection.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent DVAX News